ATE281469T1 - Inhibitor des wachstumsfaktors für gefäss- endothelzellen - Google Patents

Inhibitor des wachstumsfaktors für gefäss- endothelzellen

Info

Publication number
ATE281469T1
ATE281469T1 AT94911403T AT94911403T ATE281469T1 AT E281469 T1 ATE281469 T1 AT E281469T1 AT 94911403 T AT94911403 T AT 94911403T AT 94911403 T AT94911403 T AT 94911403T AT E281469 T1 ATE281469 T1 AT E281469T1
Authority
AT
Austria
Prior art keywords
growth factor
endothelial cells
vascular endothelial
inhibitor
vegf
Prior art date
Application number
AT94911403T
Other languages
English (en)
Inventor
Richard L Kendall
Kenneth A Thomas Jr
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE281469T1 publication Critical patent/ATE281469T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT94911403T 1993-03-25 1994-02-25 Inhibitor des wachstumsfaktors für gefäss- endothelzellen ATE281469T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3876993A 1993-03-25 1993-03-25
PCT/US1994/001957 WO1994021679A1 (en) 1993-03-25 1994-02-25 Inhibitor of vascular endothelial cell growth factor

Publications (1)

Publication Number Publication Date
ATE281469T1 true ATE281469T1 (de) 2004-11-15

Family

ID=21901791

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94911403T ATE281469T1 (de) 1993-03-25 1994-02-25 Inhibitor des wachstumsfaktors für gefäss- endothelzellen

Country Status (12)

Country Link
US (5) US5712380A (de)
EP (1) EP0694042B1 (de)
JP (1) JP3734262B2 (de)
AT (1) ATE281469T1 (de)
AU (1) AU684498B2 (de)
CA (1) CA2158745C (de)
DE (1) DE69434115T2 (de)
DK (1) DK0694042T3 (de)
ES (1) ES2230542T3 (de)
IL (1) IL109016A (de)
PT (1) PT694042E (de)
WO (1) WO1994021679A1 (de)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
GB9410533D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
US7611533B2 (en) 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
JPH09154588A (ja) 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
US7034009B2 (en) 1995-10-26 2006-04-25 Sirna Therapeutics, Inc. Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US6346398B1 (en) * 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
GB9601640D0 (en) * 1996-01-26 1996-03-27 Cancer Res Campaign Tech Ligand directed enzyme prodrug therapy
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
WO1998002543A1 (fr) 1996-07-15 1998-01-22 Chugai Research Institute For Molecular Medicine, Inc. Nouveaux facteurs analogues au vegf
AU738806B2 (en) * 1996-09-24 2001-09-27 Merck & Co., Inc. Gene therapy for inhibition of angiogenesis
US6750044B1 (en) * 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
JP3837748B2 (ja) 1997-01-17 2006-10-25 東亞合成株式会社 Ｖｅｇｆ結合性ポリペプチド
CA2328893A1 (en) * 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Vegf activity inhibitors
US6200954B1 (en) * 1998-09-04 2001-03-13 National University Of Singapore Small peptides having potent anti-angiogenic activity
US7317003B2 (en) * 1998-09-04 2008-01-08 National University Of Singapore Small peptides having anti-angiogenic and endothelial cell inhibition activity
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
HK1041447A1 (zh) * 1999-01-15 2002-07-12 Medstar Research Institute 抑制微脉管在血管壁内的扩张
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7303746B2 (en) * 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
GB9928950D0 (en) * 1999-12-07 2000-02-02 Metris Therapeutics Limited Binding protein
AU2001237256A1 (en) * 2000-03-08 2001-09-17 Neurosearch A/S A method of sensitising endothelial cells to prodrugs
EP1581615B1 (de) 2000-09-05 2010-04-28 Biosight Ltd Peptid-konjugierte antikrebs-prodrugs
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
WO2003068155A2 (en) * 2002-02-12 2003-08-21 Vanderbilt University Inhibition of vegf receptor signaling reverses tumor resistance to radiotherapy
US20040101478A1 (en) * 2002-03-29 2004-05-27 Thomas Kenneth A In vivo methods of determining activity of receptor-type kinase inhibitors
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
DK2261249T3 (en) 2002-09-12 2015-02-16 Oncotherapy Science Inc KDR peptides and vaccines comprising the same
US7432341B2 (en) * 2002-10-24 2008-10-07 Valo Hsj, Limited Partnership Cytokine receptor modulators and method of modulating cytokine receptor activity
US20040266688A1 (en) * 2003-05-14 2004-12-30 Nayak Nihar R Methods for modulating endometrium
WO2005016966A2 (en) * 2003-05-16 2005-02-24 Receptor Biologix, Inc. Intron fusion proteins, and methods of identifying and using same
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US20090155266A1 (en) * 2004-01-16 2009-06-18 Yale University Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
CA2565974A1 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
KR100897379B1 (ko) * 2004-06-08 2009-05-14 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 혈관신생-저해 키메릭 단백질 및 그 사용
US20080171033A1 (en) * 2004-08-26 2008-07-17 Chiwen Chang Compositions and methods for treating diseases associated with angiogenesis and inflammation
ATE470454T1 (de) 2004-09-13 2010-06-15 Genzyme Corp Multimere konstrukte
US8841259B2 (en) * 2005-02-24 2014-09-23 Joslin Diabetes Center Compositions and methods for treating vascular permeability
ES2435650T3 (es) 2005-02-28 2013-12-20 Oncotherapy Science, Inc. Péptidos epítopos derivados del receptor 1 del factor de crecimiento endotelial vascular y vacunas que contienen estos péptidos
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
EP1902145A4 (de) * 2005-07-13 2010-04-14 Beth Israel Hospital Verfahren zur diagnose und behandlung einer entzündungsreaktion
US9198981B2 (en) * 2006-02-01 2015-12-01 The University Of Kentucky Modulation of angiogenesis
WO2008091692A2 (en) * 2007-01-25 2008-07-31 Joslin Diabetes Center, Inc. Methods of diagnosing, treating, and preventing increased vascular permeability
TWI436775B (zh) 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
US8835183B2 (en) * 2008-01-07 2014-09-16 Ortho-Clinical Diagnostics, Inc. Determination of sFlt-1:angiogenic factor complex
WO2009149205A2 (en) * 2008-06-03 2009-12-10 Neurotech Usa, Inc. Cell lines that secrete soluble vegf receptors and uses thereof
JP2012517434A (ja) 2009-02-06 2012-08-02 ザ ジェネラル ホスピタル コーポレイション 血管病変を治療する方法
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
ES2354922B1 (es) 2009-09-02 2012-02-07 Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
WO2011028642A1 (en) 2009-09-04 2011-03-10 University Of Louisville Research Foundation, Inc. Genetic determinants of prostate cancer risk
DK2601214T3 (en) 2010-08-06 2018-02-05 Genzyme Corp VEGF ANTAGONIST COMPOSITIONS AND APPLICATIONS THEREOF
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
TWI702955B (zh) 2012-05-15 2020-09-01 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ）
EP2943190B1 (de) 2013-01-11 2019-01-02 Massachusetts Eye & Ear Infirmary Cyp450-lipid-metaboliten zur unterdrückung von entzündungen und angiogenese
US10274503B2 (en) 2013-05-08 2019-04-30 Vegenics Pty Limited Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
ES3042252T3 (en) 2014-03-17 2025-11-19 Adverum Biotechnologies Inc Compositions and methods for enhanced gene expression in cone cells
KR101844596B1 (ko) 2014-03-18 2018-04-05 한국과학기술원 당화 vegf 디코이 수용체 융합 단백질을 포함하는 안질환 치료용 조성물
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
MA40354A (fr) 2014-07-18 2017-05-24 Sanofi Sa Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer
CN114480502A (zh) 2015-03-02 2022-05-13 阿德夫拉姆生物技术股份有限公司 用于将多核苷酸玻璃体内递送到视网膜视锥的组合物和方法
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
BR112018013407A2 (en) 2015-12-30 2018-12-18 Kodiak Sciences Inc. antibodies and conjugates thereof
AU2017257169B2 (en) 2016-04-29 2021-07-08 Adverum Biotechnologies, Inc. Evasion of neutralizing antibodies by a recombinant adeno-associated virus
EP4083203B1 (de) 2016-06-16 2024-08-07 Adverum Biotechnologies, Inc. Zusammensetzungen und verfahren zur verringerung von okularer neovaskularisation
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
AU2017345470B2 (en) 2016-10-19 2023-08-03 Adverum Biotechnologies, Inc. Modified AAV capsids and uses thereof
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018170473A1 (en) 2017-03-17 2018-09-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression
EP4495136A3 (de) 2018-01-26 2025-04-23 The Regents of the University of California Verfahren und zusammensetzungen zur behandlung angiogener störungen unter verwendung von anti-vegf-mitteln
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
US12337027B2 (en) 2018-03-22 2025-06-24 The Children's Medical Center Corporation Methods and compositions relating to lung repair
TWI862583B (zh) 2019-04-26 2024-11-21 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
BR112022010113A2 (pt) 2019-11-25 2022-09-06 Univ California Inibidores de vegf de longa ação para neovascularização intraocular
CN117157309A (zh) 2021-05-28 2023-12-01 上海瑞宏迪医药有限公司 衣壳变异的重组腺相关病毒及其应用
US20250134947A1 (en) * 2021-11-02 2025-05-01 Enumita As Tri-, tetra and pentapeptides, compositions thereof and their use in the therapy of psoriasis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014748A1 (en) * 1991-02-22 1992-09-03 American Cyanamid Company Identification of a novel human receptor tyrosine kinase gene
EP0666868B2 (de) * 1992-10-28 2006-06-14 Genentech, Inc. Verwendung von anti-VEGF Antikörpern zur Behandlung von Krebs
CN1701814A (zh) * 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k－1

Also Published As

Publication number Publication date
CA2158745C (en) 2007-06-19
US20070010442A1 (en) 2007-01-11
DE69434115D1 (de) 2004-12-09
AU684498B2 (en) 1997-12-18
ES2230542T3 (es) 2005-05-01
PT694042E (pt) 2005-02-28
DK0694042T3 (da) 2005-02-14
EP0694042A4 (de) 2001-05-02
IL109016A0 (en) 1994-06-24
AU6393494A (en) 1994-10-11
US7071159B2 (en) 2006-07-04
JP3734262B2 (ja) 2006-01-11
US8034772B2 (en) 2011-10-11
US20090247460A1 (en) 2009-10-01
IL109016A (en) 2005-07-25
WO1994021679A1 (en) 1994-09-29
US5712380A (en) 1998-01-27
DE69434115T2 (de) 2005-10-27
EP0694042A1 (de) 1996-01-31
US20030120038A1 (en) 2003-06-26
EP0694042B1 (de) 2004-11-03
CA2158745A1 (en) 1994-09-29
JPH08508161A (ja) 1996-09-03
US5861484A (en) 1999-01-19

Similar Documents

Publication Publication Date Title
ATE281469T1 (de) Inhibitor des wachstumsfaktors für gefäss- endothelzellen
DE69918946D1 (de) Rezeptoren für il-18
DK1482042T3 (da) Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren
ATE350475T1 (de) Rezeptor an der oberfläche von aktivierten t- zellen:act4
DE69709727D1 (de) Parazinon thrombin inhibitoren
DK1140173T4 (da) Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
DE60203125D1 (de) Löslicher t zell rezeptor
DK1066380T3 (da) Opløselig T-cellereceptor
DK0692025T3 (da) Gærceller, der er konstrueret således, at de producerer surrogater for proteiner i feromonsystemet, og anvendelser deraf
DE69828682D1 (de) Nanomolare, non-peptidische inhibitoren von cathepsin d
ATE227739T1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
EP1117692A4 (de) Antikörper gegen tie2-antagonisten
DE69637890D1 (de) Monoklonaler antikörper für die inhibierung von hiv-1-hüllgykoprotein-vermittelte membranfusion
DK1129186T3 (da) Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
ES2057571T3 (es) Receptor de pdgf-alfa.
NO982715L (no) Endotel celle-proliferasjonsinhibitor og fremgangsmate for anvendelse
NO20010747D0 (no) Antitrombotisk middel og humanisert anti-von Willebrand faktor monoklonalt antistoff
ATE466020T1 (de) Neue isoform des gefässendothelzell wachstumshemmers (vegi)
GR3029483T3 (en) Antibodies against t-cells as therapeutics
GB2342652A (en) Polypeptides comprising a coiled-coil and an addition
DE59801230D1 (de) Endothelin-rezeptorantagonisten zur bekämpfung von hyperlipidämie
DK0929299T3 (da) Substituerede 1,2,3,4-tetrahydro-2-dibenzofuranaminer og 2-aminocyclohepta-(b)benzofuraner
AU2434400A (en) Method for the cellular high-throughput-detection of nuclear receptor ligand interactions
NO984233L (no) Cytokin kalt lerk-8
DK0889907T3 (da) Monoklonale antistoffer, som binder humant væksthormon (hGH)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0694042

Country of ref document: EP

REN Ceased due to non-payment of the annual fee